Can Fite Biofarma Ltd logo

Can Fite Biofarma Ltd

XTAE:CANF (Israel)  
₪ 0.03 (0%) Mar 27
At Loss
P/B:
1.75
Market Cap:
₪ 50.79M ($ 13.86M)
Enterprise V:
₪ 22.04M ($ 6.01M)
Volume:
5.36K
Avg Vol (2M):
4.02M
Also Trade In:

Business Description

Description
Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 155.66
Equity-to-Asset 0.57
Debt-to-Equity 0.01
Debt-to-EBITDA -0.01
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -24.1
Distress
Grey
Safe
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 94.78
9-Day RSI 81.02
14-Day RSI 70.38
6-1 Month Momentum % -23.53
12-1 Month Momentum % -7.14

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 4.1
Quick Ratio 4.1
Cash Ratio 3.59

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -89.1
Shareholder Yield % 0.3

Profitability Rank

Name Current Vs Industry Vs History
Operating Margin % -1203.29
Net Margin % -1146.78
FCF Margin % -1377.09
ROE % -138.46
ROA % -80.83
ROIC % -897.34
ROC (Joel Greenblatt) % -7805.97
ROCE % -109.7

Financials (Next Earnings Date:2024-05-31 Est.)

XTAE:CANF's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Can Fite Biofarma Ltd Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil ₪) 2.876
EPS (TTM) (₪) -0.018
Beta 0
Volatility % 62.2
14-Day RSI 70.38
14-Day ATR (₪) 0.001306
20-Day SMA (₪) 0.027
12-1 Month Momentum % -7.14
52-Week Range (₪) 0.021 - 0.041
Shares Outstanding (Mil) 1,813.93

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Can Fite Biofarma Ltd Filings

Filing Date Document Date Form
No Filing Data

Can Fite Biofarma Ltd Stock Events

Financials Calendars
Event Date Price(₪)
No Event Data

Can Fite Biofarma Ltd Frequently Asked Questions

What is Can Fite Biofarma Ltd(XTAE:CANF)'s stock price today?
The current price of XTAE:CANF is ₪0.03. The 52 week high of XTAE:CANF is ₪0.04 and 52 week low is ₪0.02.
When is next earnings date of Can Fite Biofarma Ltd(XTAE:CANF)?
The next earnings date of Can Fite Biofarma Ltd(XTAE:CANF) is 2024-05-31 Est..
Does Can Fite Biofarma Ltd(XTAE:CANF) pay dividends? If so, how much?
Can Fite Biofarma Ltd(XTAE:CANF) does not pay dividend.

Press Release

Subject Date
No Press Release